Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALE-M maintenance study in AML first remission
MOH_2022-02-22_010628Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Venetoclax + azacitidine + BSC with Best supportive care (2 arms). Started Feb 2022; status: completed.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-02-22_010628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-22_010628.